Allurion TechnologiesALUR
ALUR
About: Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Employees: 24
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
250% more call options, than puts
Call options by funds: $14K | Put options by funds: $4K
3.31% less ownership
Funds ownership: 25.91% [Q3] → 22.61% (-3.31%) [Q4]
11% less funds holding
Funds holding: 28 [Q3] → 25 (-3) [Q4]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
38% less capital invested
Capital invested by funds: $10.2M [Q3] → $6.3M (-$3.92M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.50
25%
downside
Avg. target
$9.25
176%
upside
High target
$16
378%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Chardan Capital Keay Nakae 21% 1-year accuracy 15 / 72 met price target | 25%downside $2.50 | Neutral Maintained | 27 Mar 2025 |
Roth MKM Jason Wittes 43% 1-year accuracy 9 / 21 met price target | 378%upside $16 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Based on 6 articles about ALUR published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q4 2024 Earnings Conference Call March 26, 2025 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Shantanu Gaur - Founder and Chief Executive Officer Conference Call Participants Matthew Taylor - Jefferies Josh Jennings - TD Cowen Jason Wittes - ROTH Capital Partners Keay Nakae - Chardan Capital Operator Hello, everyone, and welcome to Allurion Fourth Quarter Earnings Call. Please note that this call is being recorded.
Negative
Zacks Investment Research
1 week ago
Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates
Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $7 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $15.75 per share a year ago.
Neutral
Business Wire
1 week ago
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional pro.
Neutral
Business Wire
1 week ago
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the.
Neutral
Business Wire
3 weeks ago
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (inter.
Neutral
Business Wire
4 weeks ago
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Patent No. 12,245,962 titled “Balloon Sealing and Fill Valve”. These patents, both of which are scheduled to issue on Marc.
Neutral
Business Wire
1 month ago
Allurion to Participate in Upcoming Investor Conferences
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences. Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at 9:10 a.m. ET and host one-on-one investor meetings throughout the day on March 3, 2025, at the 45th Annual TD Cowen Healthcare Conference in Boston, Massachusetts. Dr. Gaur will also host one-on-one i.
Neutral
Business Wire
1 month ago
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company's common stock at a price of $5.23 per share and warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price o.
Neutral
Business Wire
1 month ago
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company's common stock at a price of $5.23 per share in a registered direct offering. In addition, the Company will issue to the investors warrants to purchase up to 1,800,000 shares o.
Neutral
Business Wire
1 month ago
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous studies have shown that 30% of patients di.
Charts implemented using Lightweight Charts™